Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sara M Tolaney

Showing results (1-10 of 371) with videos related to

Pageof 38
Sort By:
Clinical Advances in Hematology & Oncology : H&O|April 17, 2026
Optimal treatment for metastatic HER2+ breast cancerSara M Tolaney
Clinical Advances in Hematology & Oncology : H&O|August 7, 2024
Update on CDK4/6 inhibitors in breast cancerSara M Tolaney
Clinical Advances in Hematology & Oncology : H&O|November 10, 2023
The latest breakthrough in breast cancer treatmentSara M Tolaney
JCO Oncology Practice|June 10, 2021
Management of Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast CancerSonia Pernas, Sara M Tolaney
Current Opinion in Oncology|September 14, 2020
Targeting HER2 heterogeneity in early-stage breast cancerSonia Pernas, Sara M Tolaney
Hematology/Oncology Clinics of North America|November 26, 2022
Role of Immunotherapy in Early- and Late-Stage Triple-Negative Breast CancerStefania Morganti, Sara M Tolaney
The Lancet. Oncology|October 3, 2019
CDK4/6 inhibitors in breast cancer: a role in triple-negative disease?Shom Goel, Sara M Tolaney
Breast Cancer Research and Treatment|April 9, 2022
Clinical trial data and emerging strategies: HER2-positive breast cancerSonia Pernas, Sara M Tolaney
Lancet (London, England)|October 13, 2024
Progress in breast cancer managementPaolo Tarantino, Sara M Tolaney
The Lancet. Oncology|November 12, 2022
Fluorouracil and dose-dense adjuvant chemotherapy in breast cancer: lessons learned from the 20-year-old GIM2 trialStefania Morganti, Sara M Tolaney
Pageof 38

Showing results (1-10 of 371) with videos related to

Sort By:
Pageof 38
Clinical Advances in Hematology & Oncology : H&O|April 17, 2026
Optimal treatment for metastatic HER2+ breast cancerSara M Tolaney
Clinical Advances in Hematology & Oncology : H&O|August 7, 2024
Update on CDK4/6 inhibitors in breast cancerSara M Tolaney
Clinical Advances in Hematology & Oncology : H&O|November 10, 2023
The latest breakthrough in breast cancer treatmentSara M Tolaney
JCO Oncology Practice|June 10, 2021
Management of Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast CancerSonia Pernas, Sara M Tolaney
Current Opinion in Oncology|September 14, 2020
Targeting HER2 heterogeneity in early-stage breast cancerSonia Pernas, Sara M Tolaney
Hematology/Oncology Clinics of North America|November 26, 2022
Role of Immunotherapy in Early- and Late-Stage Triple-Negative Breast CancerStefania Morganti, Sara M Tolaney
The Lancet. Oncology|October 3, 2019
CDK4/6 inhibitors in breast cancer: a role in triple-negative disease?Shom Goel, Sara M Tolaney
Breast Cancer Research and Treatment|April 9, 2022
Clinical trial data and emerging strategies: HER2-positive breast cancerSonia Pernas, Sara M Tolaney
Lancet (London, England)|October 13, 2024
Progress in breast cancer managementPaolo Tarantino, Sara M Tolaney
The Lancet. Oncology|November 12, 2022
Fluorouracil and dose-dense adjuvant chemotherapy in breast cancer: lessons learned from the 20-year-old GIM2 trialStefania Morganti, Sara M Tolaney
Pageof 38